Defunct Company
Total Trials
5
As Lead Sponsor
4
As Collaborator
1
Total Enrollment
1,736
NCT00003253
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
Phase: Phase 2
Role: Lead Sponsor
Start: Jul 31, 1997
Completion: Not specified
NCT01640782
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach
Phase: Phase 3
Role: Collaborator
Start: Feb 28, 2005
Completion: Jan 31, 2013
NCT04801017
A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects
Start: Apr 30, 2021
Completion: Oct 31, 2021
NCT06079346
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Phase: Phase 2/3
Start: May 1, 2024
Completion: Jun 1, 2027
NCT05425576
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Start: Jun 30, 2025
Completion: Dec 31, 2029